Related references
Note: Only part of the references are listed.Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience
P. Wils et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease
Adam V. Weizman et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
Fungal infections in patients with inflammatory bowel disease: A systematic review
George A. Stamatiades et al.
MYCOSES (2018)
Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study
Carl Eriksson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)
Jiaming Qian
INTESTINAL RESEARCH (2018)
Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis
Eric D. Shah et al.
INFLAMMATORY BOWEL DISEASES (2017)
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2017)
Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015
Toshinobu Matsui et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2017)
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
Magali Lemaitre et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis
Alexander Edwards et al.
THORAX (2017)
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease
W. A. Bye et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression
Thomas G. Cotter et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Outbreak-Related Disease Burden Associated with Consumption of Unpasteurized Cow's Milk and Cheese, United States, 2009-2014
Solenne Costard et al.
EMERGING INFECTIOUS DISEASES (2017)
Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis
Chelle L. Wheat et al.
BMC GASTROENTEROLOGY (2017)
CNS Demyelination with TNF-α Blockers
Elissavet Kemanetzoglou et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents
Jordan Axelrad et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis
Edward Shelton et al.
GASTROENTEROLOGY (2016)
Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study
Ivan Guerra et al.
INFLAMMATORY BOWEL DISEASES (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prevention of Hepatitis B reactivation in the setting of immunosuppression
Venessa Pattullo
CLINICAL AND MOLECULAR HEPATOLOGY (2016)
Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis
Peter Nash et al.
RHEUMATOLOGY AND THERAPY (2016)
Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis
Sylvie Pillet et al.
INFLAMMATORY BOWEL DISEASES (2015)
The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease
Ioannis E. Koutroubakis et al.
INFLAMMATORY BOWEL DISEASES (2015)
Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy
S-J Park et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2015)
Infliximab-Related Infusion Reactions: Systematic Review
Lev Lichtenstein et al.
JOURNAL OF CROHNS & COLITIS (2015)
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
Vito Annese et al.
JOURNAL OF CROHNS & COLITIS (2015)
European Resuscitation Council Guidelines for Resuscitation 2015 Section 4. Cardiac arrest in special circumstances
Anatolij Truhlar et al.
RESUSCITATION (2015)
Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J. F. Rahier et al.
JOURNAL OF CROHNS & COLITIS (2014)
Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease
M. D. Long et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
G. W. Moran et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System
P. Deepak et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Listeriosis in patients receiving biologic therapies
M. Bodro et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2013)
Listeria infection in patients on anti-TNF treatment: Report of two cases and review of the literature
Candida Abreu et al.
JOURNAL OF CROHNS & COLITIS (2013)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2013)
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey
Raphaele Seror et al.
RHEUMATOLOGY (2013)
Vaccines and recommendations for their use in inflammatory bowel disease
Maria Dolores Sanchez-Tembleque et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines
U. Kopylov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy
T. Bessissow et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy
Xavier Mariette et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre
J. S. Wee et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
Millie D. Long et al.
GASTROENTEROLOGY (2012)
Varicella zoster virus infection in inflammatory bowel disease
Garret Cullen et al.
INFLAMMATORY BOWEL DISEASES (2012)
Prevalence and level of Listeria monocytogenes in ready-to-eat foods in Sweden 2010
S. Thisted Lambertz et al.
INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY (2012)
Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease
M. J. Casanova et al.
JOURNAL OF CROHNS & COLITIS (2012)
Anti-TNF therapy induced immune neutropenia in Crohns disease- report of 2 cases and review of literature
Shaji Sebastian et al.
JOURNAL OF CROHNS & COLITIS (2012)
Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease
Casper Steenholdt et al.
JOURNAL OF CROHNS & COLITIS (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease
Lisa J. Herrinton et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
Laurent Peyrin-Biroulet et al.
GASTROENTEROLOGY (2011)
Management of acute severe ulcerative colitis
Gert Van Assche et al.
GUT (2011)
Infliximab and adalimumab-induced psoriasis in Crohn's disease: A paradoxical side effect
Marisa Iborra et al.
JOURNAL OF CROHNS & COLITIS (2011)
Autoimmune-like syndromes during TNF blockade: does infection have a role?
Joerg C. Prinz
NATURE REVIEWS RHEUMATOLOGY (2011)
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
Johan Askling et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Autoimmune diseases induced by biological agents A double-edged sword?
Manuel Ramos-Casals et al.
AUTOIMMUNITY REVIEWS (2010)
Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease
Millie D. Long et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Hepatosplenic T-cell lymphoma and inflammatory bowel disease
Anne Thai et al.
JOURNAL OF CROHNS & COLITIS (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Neutropenia in Patients Receiving Anti-Tumor Necrosis Factor Therapy
Richard Hastings et al.
ARTHRITIS CARE & RESEARCH (2010)
Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease
M. J. Shale et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
4 Months of Rifampin Compared with 9 Months of Isoniazid for the Management of Latent Tuberculosis Infection: A Meta-analysis and Cost-Effectiveness Study That Focuses on Compliance and Liver Toxicity
Panayiotis D. Ziakas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Fatal invasive pulmonary aspergillosis associated with adalimumab therapy
M. Manz et al.
GUT (2009)
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
Laurent Beaugerie et al.
LANCET (2009)
Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients
Caroline Charpin et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Infliximab for Inflammatory Bowel Disease in Denmark 1999-2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality
Sarah Caspersen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFα therapy
Valeria D'Ovidio et al.
JOURNAL OF CLINICAL VIROLOGY (2008)
Drug-induced lupus due to anti-tumor necrosis factor α agents
Michelle F. Costa et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2008)
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease
E. J. Cepeda et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Complete heart block after infliximab therapy
Y. Sote et al.
RHEUMATOLOGY (2008)
Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease
Antonio Salar et al.
GUT (2007)
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy:: A review of 84 cases
Nirmal Kaur et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Successful etanercept use in an HIV-positive patient with rheumatoid arthritis
Primal P. Kaur et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2007)
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease
Gauree Gupta et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor
Kevin L. Winthrop
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2006)
Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions
C. Duburque et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
GR Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: Guidelines for clinical approach
Debbie M. Nathan et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment
LP Ormerod et al.
THORAX (2005)
Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy
D Wendling et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients:: need for primary prophylaxis
M Esteve et al.
GUT (2004)
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection
LH Calabrese et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection
JM Tufariello et al.
LANCET INFECTIOUS DISEASES (2003)
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease:: A prospective cohort study
S Vermeire et al.
GASTROENTEROLOGY (2003)
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
ES Chung et al.
CIRCULATION (2003)
Case reports of heart failure after therapy with a tumor necrosis factor antagonist
HJ Kwon et al.
ANNALS OF INTERNAL MEDICINE (2003)
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
MA Gardam et al.
LANCET INFECTIOUS DISEASES (2003)
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents
NR Slifman et al.
ARTHRITIS AND RHEUMATISM (2003)
Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration
SL Brown et al.
ARTHRITIS AND RHEUMATISM (2002)
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
JH Lee et al.
ARTHRITIS AND RHEUMATISM (2002)
TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection
DR Roach et al.
JOURNAL OF IMMUNOLOGY (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Tumor necrosis factor-α blockade in the treatment of rheumatoid arthritis
EC Keystone
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2001)
Infliximab for Crohn's disease in clinical practice at the mayo clinic: The first 100 patients
E Ricart et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2001)
Share Paper
